Anika Therapeutics, Inc. — Q1 2024 Form 10-Q Summary
Business context and reporting period
Anika is a global joint-preservation company focused on osteoarthritis pain management, regenerative solutions, sports medicine, and bone-preserving joint technologies. The unaudited report covers the three months ended March 31, 2024, compared with the three months ended March 31, 2023.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $40.5 million | $37.9 million | Up 7% |
| Gross profit | $24.6 million | $22.8 million | Up 8% |
| Gross margin | 61% | 60% | Up 1 point |
| Operating expenses | $29.7 million | $35.4 million | Down 16% |
| Loss from operations | $(5.1) million | $(12.6) million | Improved $7.5 million |
| Net loss | $(4.5) million | $(10.4) million | Improved $5.8 million |
| Diluted loss per share | $(0.31) | $(0.71) | Improved $0.40 |
| Adjusted EBITDA | $2.5 million | $(1.2) million | Improved $3.7 million |
Revenue by product family was $24.3 million from OA Pain Management, $13.8 million from Joint Preservation and Restoration, and $2.4 million from Non-Orthopedic products. The largest customer, DePuy Synthes Mitek Sports Medicine, represented 42% of revenue, compared with 43% in the prior-year quarter.
Cash used in operating activities was $0.1 million, versus $3.6 million used in Q1 2023. Capital expenditures were $1.8 million, and financing cash usage was $2.3 million, primarily for employee tax withholding on vested equity awards. Cash and cash equivalents declined to $68.6 million from $72.9 million at December 31, 2023. Working capital was $130.5 million, compared with $132.2 million at year-end.
Anika had no outstanding borrowings under its $75.0 million senior revolving credit facility and was in compliance with its terms. The facility may be expandable to $150.0 million subject to conditions. Lease liabilities totaled $26.3 million at March 31, 2024.
Material changes versus the prior comparable period
- Revenue increased 7%, led by 7% growth in OA Pain Management, 3% growth in Joint Preservation and Restoration, and 29% growth in Non-Orthopedic products.
- Gross margin increased to 61%, primarily because of lower acquisition-related intangible amortization, partly offset by higher inventory reserves.
- Research and development expense declined 3% to $8.2 million, primarily because of lower product development and regulatory costs.
- Selling, general and administrative expense declined 20% to $21.5 million. Q1 2023 included approximately $5.0 million of Parcus Medical arbitration settlement and other nonrecurring corporate costs.
- Q1 2024 included $0.5 million of product rationalization charges, $0.8 million of severance costs, and $0.6 million of shareholder-activism costs in management’s adjusted EBITDA reconciliation.
- Inventory increased to $49.4 million from $46.4 million at year-end, while inventory reserves increased to approximately $13.6 million from $11.7 million.
- A full valuation allowance was recorded against U.S. deferred tax assets, resulting in immaterial tax expense and a negative 1.0% effective tax rate, compared with a $1.7 million tax benefit and a 13.9% effective rate in Q1 2023.
Guidance, outlook, commentary, risks, and unusual items
The filing does not provide formal financial guidance. Management stated that cash from operations, cash on hand, and available credit are expected to be sufficient for anticipated operating needs, business investment, and capital structure requirements. Management also stated that cash requirements are expected to increase as operations expand.
Management cited continued commercial adoption of newer products, international expansion, additional U.S. regulatory approvals or clearances, and potential partnerships, acquisitions, and technology licensing as growth opportunities. Cingal, Hyalofast, and Integrity remain products or platforms relevant to the company’s regulatory and commercial strategy; Cingal is not approved for commercial use in the United States.
Key risks include dependence on a significant customer, variable strategic-partner and distributor ordering patterns, FDA and foreign regulatory requirements, product development and commercialization risks, competition, protection of intellectual property, inventory levels and reserves, foreign-currency exposure, dependence on key personnel, and the company’s recent operating losses. Management stated that routine legal proceedings are not expected to have a material adverse effect.
The company had 14.8 million common shares outstanding as of April 30, 2024. No directors or executive officers adopted or terminated a Rule 10b5-1 or other non-Rule 10b5-1 trading arrangement during the quarter. Disclosure controls and procedures were assessed as effective, with no material changes in internal control over financial reporting.
Important facts for investors to verify
- Whether revenue growth persists after favorable timing and ordering patterns contributed to Q1 results.
- Whether inventory growth and the higher reserve balance lead to additional product rationalization charges or margin pressure.
- The sustainability of positive adjusted EBITDA and progress toward positive GAAP operating income and cash flow.
- Customer concentration, particularly the approximately 42% revenue contribution from DePuy Synthes Mitek Sports Medicine.
- The timing and probability of FDA approval or clearance for Cingal and other products intended for the U.S. market.
- The impact of the U.S. deferred-tax-asset valuation allowance and continued operating losses on future tax expense and reported earnings.
- Cash usage, capital expenditures, equity-award tax-withholding requirements, and continued availability of the revolving credit facility.
- The effect of stock-based compensation, severance, shareholder-activism costs, and other adjustments when evaluating non-GAAP performance measures.